SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2017 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will present at the 2017 Wedbush PacGrow Healthcare Conference. Debanjan Ray, chief financial officer and head of corporate development will deliver a corporate overview on August 16, 2017, at 2:30 p.m. ET.
A live audio webcast of the presentation will be available through the Investors and News section of CytomX's website. An archived replay will be available for 90 days following the event.
About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of Probody™ therapeutics. Probody therapeutics exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson Cancer Center and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on Twitter.
Media Contact: Spectrum Christine Quern [email protected] 202-587-2588 Investor Contact: Trout Group Pete Rahmer [email protected] 646-378-2973
